226 related articles for article (PubMed ID: 34228543)
21. Novel C-3-(N-alkyl-aryl)-aminomethyl rifamycin SV derivatives exhibit activity against rifampicin-resistant Mycobacterium tuberculosis RpoB
Zloh M; Gupta M; Parish T; Brucoli F
Eur J Med Chem; 2021 Dec; 225():113734. PubMed ID: 34418786
[TBL] [Abstract][Full Text] [Related]
22. Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates.
Farhat MR; Sixsmith J; Calderon R; Hicks ND; Fortune SM; Murray M
J Antimicrob Chemother; 2019 Jun; 74(6):1477-1483. PubMed ID: 30793747
[TBL] [Abstract][Full Text] [Related]
23. Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex.
Saito H; Sato K; Tomioka H
Tubercle; 1988 Sep; 69(3):187-92. PubMed ID: 2855458
[TBL] [Abstract][Full Text] [Related]
24. Activity of Rifabutin and Hemi-synthetic Derivatives Against Mycobacterium abscessus.
Ramis IB; Figueiredo R; Ramos DF; Halicki PCB; von Groll A; Viveiros M; do Ceu Costa M; da Silva PEA
Med Chem; 2018; 14(4):394-399. PubMed ID: 29205119
[TBL] [Abstract][Full Text] [Related]
25. The Enzymes of the Rifamycin Antibiotic Resistome.
Surette MD; Spanogiannopoulos P; Wright GD
Acc Chem Res; 2021 May; 54(9):2065-2075. PubMed ID: 33877820
[TBL] [Abstract][Full Text] [Related]
26. Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis.
Mosaei H; Molodtsov V; Kepplinger B; Harbottle J; Moon CW; Jeeves RE; Ceccaroni L; Shin Y; Morton-Laing S; Marrs ECL; Wills C; Clegg W; Yuzenkova Y; Perry JD; Bacon J; Errington J; Allenby NEE; Hall MJ; Murakami KS; Zenkin N
Mol Cell; 2018 Oct; 72(2):263-274.e5. PubMed ID: 30244835
[TBL] [Abstract][Full Text] [Related]
27. Differential
Lee J; Ammerman N; Agarwal A; Naji M; Li SY; Nuermberger E
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168614
[TBL] [Abstract][Full Text] [Related]
28. Arabinosyltransferase C Mediates Multiple Drugs Intrinsic Resistance by Altering Cell Envelope Permeability in Mycobacterium abscessus.
Wang S; Cai X; Yu W; Zeng S; Zhang J; Guo L; Gao Y; Lu Z; Hameed HMA; Fang C; Tian X; Yusuf B; Chhotaray C; Alam MDS; Zhang B; Ge H; Maslov DA; Cook GM; Peng J; Lin Y; Zhong N; Zhang G; Zhang T
Microbiol Spectr; 2022 Aug; 10(4):e0276321. PubMed ID: 35946941
[TBL] [Abstract][Full Text] [Related]
29.
Le Run E; Arthur M; Mainardi JL
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866869
[TBL] [Abstract][Full Text] [Related]
30. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.
Dhillon J; Mitchison DA
Am Rev Respir Dis; 1992 Jan; 145(1):212-4. PubMed ID: 1309967
[TBL] [Abstract][Full Text] [Related]
31.
Mann L; Ganapathy US; Abdelaziz R; Lang M; Zimmerman MD; Dartois V; Dick T; Richter A
Microbiol Spectr; 2022 Dec; 10(6):e0276022. PubMed ID: 36377951
[TBL] [Abstract][Full Text] [Related]
32. Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria.
Combrink KD; Ramos AR; Spring S; Schmidl S; Elizondo K; Morin P; De Jesus B; Maurer FP
Bioorg Med Chem Lett; 2019 Aug; 29(16):2112-2115. PubMed ID: 31281018
[TBL] [Abstract][Full Text] [Related]
33. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey.
Senol G; Erbaycu A; Ozsöz A
J Chemother; 2005 Aug; 17(4):380-4. PubMed ID: 16167516
[TBL] [Abstract][Full Text] [Related]
34. Rifabutin: where do we stand in 2016?
Crabol Y; Catherinot E; Veziris N; Jullien V; Lortholary O
J Antimicrob Chemother; 2016 Jul; 71(7):1759-71. PubMed ID: 27009031
[TBL] [Abstract][Full Text] [Related]
35. The activity of rifabutin against Mycobacterium leprae.
Yoder LJ; Jacobson RR; Hastings RC
Lepr Rev; 1991 Sep; 62(3):280-7. PubMed ID: 1665534
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial activities of cinnamyl rifamycin derivatives, T-9 and T-11, against Mycobacterium tuberculosis and Mycobacterium avium complex (MAC) with special reference to the activities against intracellular MAC.
Sato K; Shimizu T; Dimova V; Tomioka H
Microbiol Immunol; 2006; 50(8):621-3. PubMed ID: 16924146
[TBL] [Abstract][Full Text] [Related]
37. Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases.
O'Brien RJ; Lyle MA; Snider DE
Rev Infect Dis; 1987; 9(3):519-30. PubMed ID: 3037676
[TBL] [Abstract][Full Text] [Related]
38. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis.
Dickinson JM; Mitchison DA
Tubercle; 1987 Sep; 68(3):183-93. PubMed ID: 2834843
[TBL] [Abstract][Full Text] [Related]
39. Activity of the spiropiperidyl rifamycin LM 427 on rifampicin resistant Mycobacterium tuberculosis.
Ungheri D; Della Bruna C; Sanfilippo A
G Ital Chemioter; 1984; 31(3):211-4. PubMed ID: 6100178
[No Abstract] [Full Text] [Related]
40. [In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex].
Yamamoto T; Amitani R; Kuze F; Suzuki K
Kekkaku; 1990 Dec; 65(12):805-10. PubMed ID: 2127615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
